SCHEMBL2726754

SCHEMBL2726754

CC1(C)OB(c2ccc(NC(=O)NCCC#N)cc2)OC1(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 11/20 0.46
CA2 P00918 11/20 0.46
CA9 Q16790 11/20 0.46
CA12 O43570 1/20 0.43
CA3 P07451 1/20 0.43
CA4 P22748 1/20 0.43
CA6 P23280 1/20 0.43
CA5A P35218 1/20 0.43
CA7 P43166 1/20 0.43
CA14 Q9ULX7 1/20 0.43
CA5B Q9Y2D0 1/20 0.43
PDGFRB P09619 1/20 0.40
KDR P35968 1/20 0.40
ESR2 Q92731 1/20 0.40
MTOR P42345 1/20 0.39
CXCR2 P25025 1/20 0.39
CNR1 P21554 2/20 0.38
LPL P06858 1/20 0.38
LIPG Q9Y5X9 1/20 0.38
NPC1 O15118 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL443866 0.84 MEN1 (0.52) CA1CA2CA9CA12CA3
SCHEMBL2380393 0.84 CA1 (0.49) CA1CA2CA9CA12CA3
SCHEMBL444777 0.83 CA1 (0.48) CA1CA2CA9CA12CA3
SCHEMBL3732362 0.83 CA1 (0.48) CA1CA2CA9CA12CA3
SCHEMBL440627 0.83 CNR1 (0.57) CA1CA2CA9CA12CA3
SCHEMBL22683677 0.82 HDAC1 (0.54) CA1CA2CA9CA12CA3
SCHEMBL15550038 0.82 CA1 (0.57) CA1CA2CA9CA12CA3
SCHEMBL118986 0.81 CA1 (0.51) CA1CA2CA9CA12CA3
SCHEMBL31144570 0.81 POLB (0.57) CA1CA2CA9CA12CA3
SCHEMBL16899484 0.80 CA1 (0.50) CA1CA2CA9CA12CA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2445346-A1 OXO-HETEROCYCLE FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE Genentech, Inc. (US) 2012-05-02 EP disclosed
US-20100331305-A1 OXO-HETEROCYCLE FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE GENENTECH, INC. (US) 2010-12-30 US disclosed
US-20100331305-A1 OXO-HETEROCYCLE FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE GENENTECH, INC. (US) 2010-12-30 US disclosed
US-20100331305-A1 OXO-HETEROCYCLE FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE GENENTECH, INC. (US) 2010-12-30 US disclosed
WO-2010151601-A1 OXO-HETEROCYCLE FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE GENENTECH, INC. (US) 2010-12-29 WO disclosed
WO-2010151601-A1 OXO-HETEROCYCLE FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE GENENTECH, INC. (US) 2010-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331305-A1 OXO-HETEROCYCLE FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE MTOR, PIK3CA, RICTOR CA1 4701/4885CA2 4186/4885CA9 4574/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.